Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Blood
|
February 16, 2023
BRAF-negative, CD103-negative hairy cell leukemia
Adam Jimenez, Wen Shuai
Journal of Forensic Sciences
|
May 18, 2021
A pen as an intermediate target becomes a secondary projectile
Adam Jimenez, Mark A Giffen
Pediatric Blood & Cancer
|
August 26, 2024
Systemic EBV-positive T-cell lymphoma of childhood with unusual cytogenetic findings and family history of Still's disease-associated recurrent macrophage activation syndrome
Adam Jimenez, Luis F Carrillo, Eric D Carlsen
Pediatric Nephrology (Berlin, Germany)
|
August 13, 2019
Does MEST-C score predict outcomes in pediatric Henoch-Schönlein purpura nephritis?
Adam Jimenez, Ashton Chen, Jen-Jar Lin, et al.
Clinical Biochemistry
|
April 2, 2024
Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab
Adam Jimenez, Ashley Rose Scholl, Bangchen Wang, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Blood
|
February 16, 2023
BRAF-negative, CD103-negative hairy cell leukemia
Adam Jimenez, Wen Shuai
Journal of Forensic Sciences
|
May 18, 2021
A pen as an intermediate target becomes a secondary projectile
Adam Jimenez, Mark A Giffen
Pediatric Blood & Cancer
|
August 26, 2024
Systemic EBV-positive T-cell lymphoma of childhood with unusual cytogenetic findings and family history of Still's disease-associated recurrent macrophage activation syndrome
Adam Jimenez, Luis F Carrillo, Eric D Carlsen
Pediatric Nephrology (Berlin, Germany)
|
August 13, 2019
Does MEST-C score predict outcomes in pediatric Henoch-Schönlein purpura nephritis?
Adam Jimenez, Ashton Chen, Jen-Jar Lin, et al.
Clinical Biochemistry
|
April 2, 2024
Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab
Adam Jimenez, Ashley Rose Scholl, Bangchen Wang, et al.
Page
of 1